{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:11:01Z","timestamp":1771513861030,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04049-y","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T23:51:55Z","timestamp":1757634715000},"page":"789-803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oligometastatic disease in pancreatic cancer: is there a role for curative-intent surgery? A narrative review"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5183-5564","authenticated-orcid":false,"given":"C\u00e9sar P.","family":"Ram\u00edrez-Plaza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Rold\u00f3n-Golet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"P\u00e9rez-Daga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Pereira-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"issue":"43","key":"4049_CR1","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"A McGuigan","year":"2018","unstructured":"McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846\u201361. https:\/\/doi.org\/10.3748\/wjg.v24.i43.4846.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"4049_CR2","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver and pancreas cancers in the United States. Cancers Res. 2014;74(11):2913\u201321. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0155.","journal-title":"Cancers Res"},{"issue":"10242","key":"4049_CR3","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(20)30974-0.","journal-title":"Lancet"},{"issue":"9","key":"4049_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326(9):851\u201362. https:\/\/doi.org\/10.1001\/jama.2021.13027.","journal-title":"JAMA"},{"issue":"6","key":"4049_CR5","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.surg.2014.02.001","volume":"155","author":"M Bockhorn","year":"2014","unstructured":"Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery. Surgery. 2014;155(6):977\u201388. https:\/\/doi.org\/10.1016\/j.surg.2014.02.001.","journal-title":"Surgery"},{"issue":"9","key":"4049_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00769-1","volume":"21","author":"G Perri","year":"2020","unstructured":"Perri G, Prakash L, Katz MHG. Defining and treating borderline resectable pancreatic cancer. Curr Treat Options Oncol. 2020;21(9):71. https:\/\/doi.org\/10.1007\/s11864-020-00769-1.","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"4049_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jamcollsurg.2007.09.021","volume":"206","author":"R White","year":"2008","unstructured":"White R, Winston C, Gonen M, D\u2019Angelica M, Jarnagin W, Fong Y, et al. Current utility of staging laparoscopy for pancreatic and peripancreatic resection. J Am Coll Surg. 2008;206(3):445\u201350.","journal-title":"J Am Coll Surg"},{"issue":"11","key":"4049_CR8","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1056\/NEJMra1404198","volume":"371","author":"DP Ryan","year":"2014","unstructured":"Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039\u201349. https:\/\/doi.org\/10.1056\/NEJMra1404198.","journal-title":"N Engl J Med"},{"issue":"12","key":"4049_CR9","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/bjs.11295","volume":"106","author":"M Tanaka","year":"2019","unstructured":"Tanaka M, Mihaljevic AL, Probst P, Heckler M, Klaiber U, Heger U, et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Br J Surg. 2019;106(12):1590\u2013601. https:\/\/doi.org\/10.1002\/bjs.11295.","journal-title":"Br J Surg"},{"issue":"1","key":"4049_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8\u201310. https:\/\/doi.org\/10.1200\/JCO.1995.13.1.8.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4049_CR11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","volume":"8","author":"RR Weichselbaum","year":"2011","unstructured":"Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378\u201382. https:\/\/doi.org\/10.1038\/nrclinonc.2011.44.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"4049_CR12","doi-asserted-by":"publisher","first-page":"8491","DOI":"10.18632\/oncotarget.3455","volume":"6","author":"DK Reyes","year":"2015","unstructured":"Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget. 2015;6(11):8491\u2013524. https:\/\/doi.org\/10.18632\/oncotarget.3455.","journal-title":"Oncotarget"},{"issue":"10","key":"4049_CR13","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(18)30571-0","volume":"19","author":"FE Lecouvet","year":"2018","unstructured":"Lecouvet FE, Oprea-Lager DE, Liu Y, Ost P, Bidaut L, Collette L, et al. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncol. 2018;19(10):e534\u201345. https:\/\/doi.org\/10.1016\/S1470-2045(18)30571-0.","journal-title":"Lancet Oncol"},{"issue":"12","key":"4049_CR14","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/j.jtho.2019.05.037","volume":"14","author":"N Giaj-Levra","year":"2019","unstructured":"Giaj-Levra N, Giaj-Levra M, Durieux V, Novello S, Besse B, Hasan B, et al. Defining synchronous oligometastatic non-small cell lung cancer: a systematic review. J Thorac Oncol. 2019;14(12):2053\u201361. https:\/\/doi.org\/10.1016\/j.jtho.2019.05.037.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"4049_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4143\/crt.2022.329","volume":"54","author":"CH Rim","year":"2022","unstructured":"Rim CH, Cho WK, Lee JH, Kim YS, Suh YG, Kin KH, et al. Role of local treatment for oligometastasis: a comparability-based meta-analysis. Cancer Res Treat. 2022;54(4):953\u201369. https:\/\/doi.org\/10.4143\/crt.2022.329.","journal-title":"Cancer Res Treat"},{"key":"4049_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Guckernberger M, Gomez D, Hover M, Ivengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radother Oncol. 2020;148:157\u201366.","journal-title":"Radother Oncol"},{"issue":"1","key":"4049_CR17","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bpuma AB, Collette L, Dekker A, de Souza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(19)30718-1.","journal-title":"Lancet Oncol"},{"issue":"12","key":"4049_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028650","volume":"6","author":"YA Lussier","year":"2011","unstructured":"Lussier YA, Xing HR, Salama JK, Khodarev NH, Huang Y, Zhang Q, et al. MicroRNA expresi\u00f3n characterizes oligometastasis (es). PLoS ONE. 2011;6(12):e28560. https:\/\/doi.org\/10.1371\/journal.pone.0028650.","journal-title":"PLoS ONE"},{"issue":"6","key":"4049_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102067","volume":"8","author":"CS Leonhardt","year":"2023","unstructured":"Leonhardt CS, Stamm T, Hank T, Prager G, Strobel O. Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus. ESMO Open. 2023;8(6):102067. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102067.","journal-title":"ESMO Open"},{"issue":"1","key":"4049_CR20","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1186\/s12885-019-6448-9","volume":"19","author":"AI Damanakis","year":"2019","unstructured":"Damanakis AI, Ostertag L, Waldschmidt D, K\u00fctting F, Ouaas A, Plum P, et al. Proposal for a definition of \u201coligometastatic disease in pancreatic cancer.\u201d BMC Cancer. 2019;19(1):1261. https:\/\/doi.org\/10.1186\/s12885-019-6448-9.","journal-title":"BMC Cancer"},{"issue":"8","key":"4049_CR21","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.21873\/anticanres.15189","volume":"41","author":"M Yamanaka","year":"2021","unstructured":"Yamanaka M, Hayashi M, Yamada S, Sonohara F, Takami H, Inokawa Y, et al. A possible definition of oligometastasis in pancreatic cancer and associated survival outcomes. Anticancer Res. 2021;41(8):3933\u201340. https:\/\/doi.org\/10.21873\/anticanres.15189.","journal-title":"Anticancer Res"},{"issue":"3","key":"4049_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ags3.12753","volume":"8","author":"R Saito","year":"2023","unstructured":"Saito R, Ban D, Mizui T, Takamoto T, Nara S, Esaki M, et al. Oligo-like liver metastasis: a novel prognostic indicator to improve survival in pancreatic cancer. Ann Gastroenterol Surg. 2023;8(3):481\u20139.","journal-title":"Ann Gastroenterol Surg"},{"issue":"4","key":"4049_CR23","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3390\/cancers11040497","volume":"11","author":"DJ Birnbaum","year":"2019","unstructured":"Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E. Head and body\/tail pancreatic carcinomas are not the same tumors. Cancers (Basel). 2019;11(4):497. https:\/\/doi.org\/10.3390\/cancers11040497.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"4049_CR24","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1007\/s10147-022-02131-x","volume":"27","author":"T Sasaki","year":"2022","unstructured":"Sasaki T, Nishiwada S, Nakagawa K, Nagai M, Terai T, Hokuto D, et al. Integrative analysis identifies activated anti-tumor immune microenvironment in lung metastasis of pancreatic cancer. Int J Clin Oncol. 2022;27(5):948\u201357. https:\/\/doi.org\/10.1007\/s10147-022-02131-x.","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"4049_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jhbp.1184","volume":"30","author":"T Takeda","year":"2023","unstructured":"Takeda T, Sasaki T, Okamoto T, Kasuga A, Matsuyama M, Ozaka M, et al. Outcomes of pancreatic cancer with liver oligometastasis. J Hepatobiliary Pancreat. 2023;30(2):229\u201339. https:\/\/doi.org\/10.1002\/jhbp.1184.","journal-title":"J Hepatobiliary Pancreat"},{"issue":"1","key":"4049_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znad417","volume":"111","author":"K Omiya","year":"2024","unstructured":"Omiya K, Maekawa A, Oba A, Inoue Y, Hirose Y, Kobayashi K, et al. A proposal of ABCD metastasectomy criteria for synchronous\/metachronous metastatic pancreatic cancer in the era of multidisciplinary treatment. Br J Surg. 2024;111(1):znad417. https:\/\/doi.org\/10.1093\/bjs\/znad417.","journal-title":"Br J Surg"},{"issue":"4","key":"4049_CR27","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1001\/archsurg.1997.01430280012001","volume":"132","author":"B Cady","year":"1997","unstructured":"Cady B. Basic principles in surgical oncology. Arch Surg. 1997;132(4):338\u201346. https:\/\/doi.org\/10.1001\/archsurg.1997.01430280012001.","journal-title":"Arch Surg"},{"issue":"6","key":"4049_CR28","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403\u201313. https:\/\/doi.org\/10.1200\/JCO.1997.15.6.2403.","journal-title":"J Clin Oncol"},{"issue":"19","key":"4049_CR29","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"issue":"18","key":"4049_CR30","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean G, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med"},{"issue":"18","key":"4049_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184464","volume":"15","author":"PW Underwood","year":"2023","unstructured":"Underwood PW, Herremans KM, Neal D, Riner AN, Nassour I, Hughes SJ, et al. Changing practice patterns and improving survival for patients with pancreatic ductal adenocarcinoma. Cancers (Basel). 2023;15(18):4464. https:\/\/doi.org\/10.3390\/cancers15184464.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4049_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102944","volume":"9","author":"L Weiss","year":"2024","unstructured":"Weiss L, Fischer LE, Heinemann V, Gieseler F, Hoehler T, Mayerle J, et al. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group. ESMO Open. 2024;9(4):102944. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102944.","journal-title":"ESMO Open"},{"key":"4049_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/939350","author":"F Klein","year":"2012","unstructured":"Klein F, Puhl G, Guckelberger O, Pelzer U, Pullankavumkal JR, Guel S, et al. The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma. Gastroenterol Res Pract. 2012. https:\/\/doi.org\/10.1155\/2012\/939350.","journal-title":"Gastroenterol Res Pract"},{"issue":"1","key":"4049_CR34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.surg.2016.02.019","volume":"160","author":"M Tachezy","year":"2016","unstructured":"Tachezy M, Gebauer F, Janot M, Uhl W, Zerbi A, Montorsi M, et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016;160(1):136\u201344. https:\/\/doi.org\/10.1016\/j.surg.2016.02.019.","journal-title":"Surgery"},{"issue":"2","key":"4049_CR35","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ejso.2016.10.023","volume":"43","author":"T Hackert","year":"2017","unstructured":"Hackert T, Niesen W, Hinz U, Tjaden C, Strobel O, Ulrich A, et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2017;43(2):358\u201363. https:\/\/doi.org\/10.1016\/j.ejso.2016.10.023.","journal-title":"Eur J Surg Oncol"},{"key":"4049_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/cancers14010057","volume":"14","author":"TM Pausch","year":"2021","unstructured":"Pausch TM, Liu X, Cui J, et al. Survival benefit of resection surgery for pancreatic ductal adenocarcinoma with liver metastases: a propensity score-matched SEER database analysis. Cancers (Basel). 2021;14:57. https:\/\/doi.org\/10.3390\/cancers14010057.","journal-title":"Cancers (Basel)"},{"key":"4049_CR37","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.surg.2021.12.029","volume":"171","author":"A Hamad","year":"2022","unstructured":"Hamad A, Underhill J, Ansari A, Thayaparan V, Cloyd JM, Li y, et al. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: an analysis of the National Cancer Database. Surgery. 2022;171:1464\u201370. https:\/\/doi.org\/10.1016\/j.surg.2021.12.029.","journal-title":"Surgery"},{"issue":"4","key":"4049_CR38","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.surg.2022.03.003","volume":"172","author":"P Bachellier","year":"2022","unstructured":"Bachellier P, Addeo P, Averous G, Dufour P. Resection of pancreatic adenocarcinomas with synchronous liver metastases: a retrospective study of prognostic factors for survival. Surgery. 2022;172(4):1425\u20131250. https:\/\/doi.org\/10.1016\/j.surg.2022.03.003.","journal-title":"Surgery"},{"issue":"8","key":"4049_CR39","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/jhbp.1303","volume":"30","author":"M Nagai","year":"2023","unstructured":"Nagai M, Wright MJ, Ding D, Thompson ED, Javed AA, Weiss MJ, et al. Oncologic resection of pancreatic cancer with isolated liver metastasis: favorable outcomes in select patients. J Hepatobiliary Pancreat Sci. 2023;30(8):1025\u201335. https:\/\/doi.org\/10.1002\/jhbp.1303.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"5","key":"4049_CR40","doi-asserted-by":"publisher","first-page":"e1089","DOI":"10.1097\/SLA.0000000000005481","volume":"277","author":"T Hank","year":"2023","unstructured":"Hank T, Klaiber U, Hinz U, Sch\u00fctte D, Leonhardt CS, Bergmann F, et al. Oncological outcome of conversion surgery after preoperative chemotherapy for metastatic pancreatic cancer. Ann Surg. 2023;277(5):e1089\u201398. https:\/\/doi.org\/10.1097\/SLA.0000000000005481.","journal-title":"Ann Surg"},{"issue":"8","key":"4049_CR41","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1245\/s10434-017-5885-4","volume":"24","author":"I Frigerio","year":"2017","unstructured":"Frigerio I, Regi P, Giardino A, Scopelliti F, Girelli R, Bassi C, et al. Downstaging in stage IV pancreatic cancer: a new population eligible for surgery? Ann Surg Oncol. 2017;24(8):2397\u2013403. https:\/\/doi.org\/10.1245\/s10434-017-5885-4. (Epub 2017 May 17).","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4049_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s13304-020-00710-z","volume":"72","author":"S Crippa","year":"2020","unstructured":"Crippa S, Cirocchi R, Weiss MJ, Partelli S, Reni M, Wolfgang CL, et al. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Update Surg. 2020;72(1):39\u201345. https:\/\/doi.org\/10.1007\/s13304-020-00710-z.","journal-title":"Update Surg"},{"issue":"11","key":"4049_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113402","volume":"12","author":"O De Simoni","year":"2020","unstructured":"De Simoni O, Scarpa M, Tonello M, Pilati P, Tolin F, Spolverato Y, et al. Oligometastatic pancreatic cancer to the liver in the era of neoadjuvant chemotherapy: which role for conversion surgery? A systematic review and meta-analysis. Cancers (Basel). 2020;12(11):3402. https:\/\/doi.org\/10.3390\/cancers12113402.","journal-title":"Cancers (Basel)"},{"issue":"3\u20134","key":"4049_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000313532","volume":"44","author":"F D\u00fcnschede","year":"2010","unstructured":"D\u00fcnschede F, Will L, von Langsdorf C, M\u00f6hler M, Galle PR, Otto G, et al. Treatment of metachronous and simultaneous liver metastases of pancreatic cancer. Eur Surg Res. 2010;44(3\u20134):209\u201313. https:\/\/doi.org\/10.1159\/000313532.","journal-title":"Eur Surg Res"},{"issue":"1","key":"4049_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s13304-015-0283-6","volume":"67","author":"N Zanini","year":"2015","unstructured":"Zanini N, Lombardi R, Masetti M, Giordano M, Landolfo G, Jovine E, et al. Surgery for isolated liver metastases from pancreatic cancer. Update Surg. 2015;67(1):19\u201325. https:\/\/doi.org\/10.1007\/s13304-015-0283-6.","journal-title":"Update Surg"},{"key":"4049_CR46","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.suronc.2020.08.005","volume":"35","author":"C Schwarz","year":"2020","unstructured":"Schwarz C, Fitschek F, Primavesi F, St\u00e4ttner S, Margonis GA, Weiss MA, et al. Metachronous hepatic resection for liver only pancreatic metastases. Surg Oncol. 2020;35:169\u201373. https:\/\/doi.org\/10.1016\/j.suronc.2020.08.005.","journal-title":"Surg Oncol"},{"key":"4049_CR47","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00423-023-03009-w","volume":"408","author":"Y Shibata","year":"2023","unstructured":"Shibata Y, Uemura K, Sumiyoshi T, Okada K, Otsuka H, Serikawa M, et al. Surgical resection for liver recurrence after curative resection of pancreatic ductal adenocarcinoma. Langenbecks Arch Surg. 2023;408:280. https:\/\/doi.org\/10.1007\/s00423-023-03009-w.","journal-title":"Langenbecks Arch Surg"},{"issue":"9","key":"4049_CR48","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.3390\/cancers14092067","volume":"14","author":"WG Yun","year":"2022","unstructured":"Yun WG, Kwon W, Hang Y, Sohn HJ, Kim HS, Lee M, et al. Can Surgical Resection of Metastatic Lesions Be Beneficial to Pancreatic Ductal Adenocarcinoma Patients with Isolated Lung Metastasis? Cancers (Basel). 2022;14(9):2067. https:\/\/doi.org\/10.3390\/cancers14092067.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4049_CR49","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1038\/s41598-020-61487-0","volume":"10","author":"Q Liu","year":"2020","unstructured":"Liu Q, Zhang R, Michalski CW, Liao Q, Kleeff J. Surgery for synchronous and metachronous single-organ metastasis of pancreatic cancer: a SEER database analysis and systematic literature review. Sci Rep. 2020;10(1):4444. https:\/\/doi.org\/10.1038\/s41598-020-61487-0.","journal-title":"Sci Rep"},{"issue":"8","key":"4049_CR50","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.hpb.2018.12.002","volume":"21","author":"VP Groot","year":"2019","unstructured":"Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart R, van Ososten AF, et al. Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. HPB (Oxford). 2019;21(8):998\u20131008. https:\/\/doi.org\/10.1016\/j.hpb.2018.12.002.","journal-title":"HPB (Oxford)"},{"key":"4049_CR51","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jtcvs.2016.02.066","volume":"152","author":"LA Robinson","year":"2016","unstructured":"Robinson LA, Tanvetyanon T, Springett G, Fontaine J, Toloza E, et al. Pulmonary metastasectomy for suspected pancreaticobiliary cancer. J Thorac Cardiovasc Surg. 2016;152:75\u201382.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"4049_CR52","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/jhbp.1127","volume":"29","author":"Y Homma","year":"2022","unstructured":"Homma Y, Endo I, Matsuyama R, Sho M, Mizuno S, Seyama y, et al. Outcomes of lung metastasis from pancreatic cancer: a nationwide multicenter analysis. J Hepatobiliary Pancreat Sci. 2022;29(5):552\u201361. https:\/\/doi.org\/10.1002\/jhbp.1127.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"5","key":"4049_CR53","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ejso.2016.02.003","volume":"42","author":"S Paiella","year":"2016","unstructured":"Paiella S, Sandini M, Gianotti L, Butturini G, Salvia R, Bassi C. The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2016;42(5):616\u201324. https:\/\/doi.org\/10.1016\/j.ejso.2016.02.003.","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"4049_CR54","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.pan.2021.03.006","volume":"21","author":"T Takeda","year":"2021","unstructured":"Takeda T, Sasaki T, Mie T, Furukawa T, Yamada Y, Kasuga A, et al. Improved prognosis of pancreatic cancer patients with peritoneal metastasis. Pancreatology. 2021;21(5):903\u201311. https:\/\/doi.org\/10.1016\/j.pan.2021.03.006.","journal-title":"Pancreatology"},{"issue":"Suppl 1","key":"4049_CR55","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.21037\/jgo-20-243","volume":"12","author":"S Yamada","year":"2021","unstructured":"Yamada S, Fujii T, Yamamoto T, Takami H, Yoshioka I, Yamaki S, et al. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. J Gastrointest Oncol. 2021;12(Suppl 1):S110\u20137. https:\/\/doi.org\/10.21037\/jgo-20-243.","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"4049_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051354","volume":"14","author":"T Yamamoto","year":"2022","unstructured":"Yamamoto T, Satoi S, Yamaki S, Hashimoto D, Ishida M, Ikeura T, et al. Intraperitoneal paclitaxel treatment for patients with pancreatic ductal adenocarcinoma with peritoneal dissemination provides a survival benefit. Cancers (Basel). 2022;14(5):1354. https:\/\/doi.org\/10.3390\/cancers14051354.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"4049_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033452","volume":"9","author":"M Wei","year":"2019","unstructured":"Wei M, Shi S, Hua J, Xu J, Yu X. Simultaneous resection of the primary tumor and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastases: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1). BMJ Open. 2019;9(12):e033452. https:\/\/doi.org\/10.1136\/bmjopen-2019-033452.","journal-title":"BMJ Open"},{"issue":"1","key":"4049_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06049-7","volume":"23","author":"T Yamamoto","year":"2022","unstructured":"Yamamoto T, Fujii T, Hirano S, Motoi F, Honda G, Uemura K, et al. Randomized pase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study). Trials. 2022;23(1):119.","journal-title":"Trials"},{"issue":"1","key":"4049_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13573-7","volume":"25","author":"M Ghadimi","year":"2025","unstructured":"Ghadimi M, Pelzer U, Besselink MG, Siveke J, Telgmann R, Braren R, et al. Study protocol of the METAPANC trial \u2013 intensified treatment in patients with local operable but oligometastatic pancreatic cancer \u2013 multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial. BMC Cancer. 2025;25(1):208. https:\/\/doi.org\/10.1186\/s12885-025-13573-7.","journal-title":"BMC Cancer"},{"issue":"1","key":"4049_CR60","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1186\/s12885-021-08966-3","volume":"21","author":"F Gebauer","year":"2021","unstructured":"Gebauer F, Damanakis AI, Popp F, Quass A, K\u00fctting F, Lutz K, et al. Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil\/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC). BMC Cancer. 2021;21(1):1239. https:\/\/doi.org\/10.1186\/s12885-021-08966-3.","journal-title":"BMC Cancer"},{"key":"4049_CR61","unstructured":"NCT05271110. Available online: https:\/\/clinicaltrials.gov\/study\/NCT05271110#study-plan (accessed on 17 December 2023)"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04049-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04049-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04049-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:19:25Z","timestamp":1771510765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04049-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":61,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4049"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04049-y","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}